View Financial HealthCurative Biotechnology 배당 및 자사주 매입배당 기준 점검 0/6Curative Biotechnology 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0.7%자사주 매입 수익률총 주주 수익률0.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000공시 • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock공시 • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42공시 • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).공시 • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6공시 • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605공시 • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.공시 • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.공시 • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unit공시 • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.공시 • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.공시 • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.공시 • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.공시 • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CUBT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CUBT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Curative Biotechnology 배당 수익률 vs 시장CUBT의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CUBT)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (CUBT) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CUBT 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CUBT 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CUBT 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CUBT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:27종가2026/05/21 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Curative Biotechnology, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Dec 23Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering.Curative Biotechnology, Inc. has withdrawn its Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,500,000
공시 • May 08Curative Biotechnology, Inc. has filed a Follow-on Equity Offering.Curative Biotechnology, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
공시 • Feb 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6 Discount Per Security: $0.42
공시 • Jan 06Curative Biotechnology, Inc. Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyCurative Biotechnology Inc. announced that it has successfully completed its Investigational New Drug (IND) enabling Tolerance and Toxicology Study of Metformin HCL Solution by Topical Instillation (eye drops) in Rabbits. Macular Degeneration is a common eye disorder among people over 50 causing blurred or reduced central vision due from the deterioration of the inner layers of the macula. The macula is the part of the retina that gives the eye clear vision in the direct line of sight. Dry AMD accounts for 80-90% of all age-related macular degeneration (AMD cases), while wet AMD represents 10-20% of patient cases. Currently there are no approved drug treatments for Dry AMD or Geographic Atrophy (late-stage dry AMD).
공시 • Nov 08Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million.Curative Biotechnology, Inc. has filed an IPO in the amount of $7.999998 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,333,333 Price\Range: $6
공시 • Nov 01Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million.Curative Biotechnology, Inc. has withdrawn its IPO in the amount of $8 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,553,398 Price\Range: $5.15 Discount Per Security: $0.3605
공시 • Jun 17Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of DirectorsCurative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property. Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.
공시 • May 13Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of DirectorsCurative Biotechnology Inc. announced that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.
공시 • Apr 16Curative Biotechnology, Inc. has filed an IPO.Curative Biotechnology, Inc. has filed an IPO. Security Name: Units Security Type: Equity/Derivative Unit
공시 • Nov 25Curative Biotechnology Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular DegenerationCurative Biotechnology, Inc. announced the company has advanced into ocular tolerance evaluation of various metformin eye drop formulations. As a significant step towards moving into human clinical trials, the current studies focus on tolerability and pharmacokinetics which will assess the ocular tissue distribution after topical ocular delivery of metformin. These studies will aid in optimization of the formulation and build evidence to ensure adequate exposure and safety via topical ocular delivery, which will support the company to move into Good Laboratory Practice (GLP) toxicology studies for an IND filing. Ocular tolerance includes observations at dosing, general clinical observations twice daily (evaluation of behavior/clinical signs with particular attention paid to the eyes), ophthalmic examinations by a board-certified veterinary ophthalmologist according to the modified Hackett-McDonald scoring scale, and ocular histopathology.
공시 • Feb 12+ 1 more updateConnectyx Technologies Holdings Group, Inc. Appoints I Richard Garr as Chief Executive OfficerConnectyx Technologies Holdings Group, Inc. announced the addition of I Richard Garr as chief executive officer and general counsel. Mr. Garr was former president & CEO and general counsel, Neuralstem Inc. (1997-2016), where he had responsibility and oversight worldwide for all operations of a leading regenerative medicine company including: IP portfolio prosecution; defense and management; worldwide regulatory affairs; worldwide licensing and business development and collaborations; capital raises; social media and public relations programs. Mr. Garr is also the founder and managing partner of Access Hope CRO, the first CRO dedicated exclusively to Right to Try treatment programs, at scale, to accelerate drug development. Mr. Garr's nonprofit affiliations and work include: a co-founding director of the Starlight Mid Atlantic Foundation; The First Star Foundation and the First Star Institute; a group of charities involved in helping seriously ill children and abused and neglected children; a director on the National Advisory Counsel for Right To Try; a group involved in expanding access to clinical trial stage treatments for dying patients; in addition to considerable work with, and for, various state chapters of the ALS Society of America, the National Brain Tumor Foundation and the Paralyzed Veterans of America.
공시 • Feb 05Connectyx Announces Grant of Exclusive Worldwide License from National Institutes of Health for Repurposing Metformin to Treat Degenerative Eye DiseaseConnectyx Technologies Holdings Group, Inc. announced it has entered into an Exclusive Patent License Agreement to practice inventions contained within the patent applications listed below with the National Eye Institute (NEI), of the National Institutes of Health (NIH), including the repurposed use of Metformin to treat Retinal Degeneration (RD). The license patent rights include U.S. provisional patent application No. 62/899,899 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 13, 2019 (E-227-2017-US-01); International Patent Application No.: PCT/US2020/050540 and entitled, "Druggable Targets to Treat Retinal Degeneration" filed September 11, 2020 (E-227-2017-PCT-O2); and U.S. and foreign patent applications claiming priority to the applications. The territory for the exclusive license is worldwide. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt disease, retinitis pigmentosa, choroideremia, late-onset retinal degeneration (L-ORD), and age-related macular degeneration (AMD). In the United States, 11 million people are affected by some form of AMD.
공시 • Nov 25Connectyx Announces Appointment of Michael K. Fish to Board of DirectorsConnectyx Technologies Holdings Group, Inc. announced that it has added Michael K. Fish to their Board of Directors. Mr. Fish founded a Certified PublicAccounting firm in South Florida and possesses expertise in all areas of accounting, finance, and taxes for business including experience in the medical, wholesale, and professional services sectors. Mr. Fish has agreed to serve as the Chairman of the Audit Committee of the Board.
공시 • Oct 18Connectyx Announces Grant of License from National Institutes of Health for Use of Novel Monoclonal Antibody to Treat GlioblastomaConnectyx Technologies Holdings Group, Inc. announced that, it has entered into an Exclusive Evaluation and Commercialization Option License Agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for use of a novel monoclonal antibody in an antibody-drug conjugate to treat brain cancer. While the field of use covers treating adult and pediatric Glioblastomas, the Company is targeting pediatric Glioblastoma, an orphan disease, as the first indication for this product.